Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report

Wang,Yue  Feng; Xiang,Xianhong; Pei,Xiaojuan; Li,Shuhua; Tang,Cuilan; Wang,Liantang; Ke,Zun‑Fu

doi:10.3892/ol.2014.2321

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report

Authors:
- Yue Feng Wang
- Xianhong Xiang
- Xiaojuan Pei
- Shuhua Li
- Cuilan Tang
- Liantang Wang
- Zun‑Fu Ke
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Interventional Radiology, Huizhou Municipal Central Hospital, Huizhou, Guangdong 516001, P.R. China, Department of Pathology, Huizhou Municipal Central Hospital, Huizhou, Guangdong 516001, P.R. China
Published online on: July 4, 2014 https://doi.org/10.3892/ol.2014.2321
Pages: 1039-1042

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of mortality among malignant diseases in humans worldwide. During the last decade, molecular targeted therapies for non‑small cell lung cancer using ﬁrst‑generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib, have been shown to be a promising approach for patients harboring activating mutations in EGFR. The current study reports a 77‑year‑old patient diagnosed with adenocarcinoma harboring L858R and T790M point mutations in the EGFR gene. The patient was treated with gefitinib as the second‑line therapy, but no clinical benefit was observed. As the majority of patients with lung cancer receiving EGFR‑TKI therapy acquire resistance, repeated biopsies and detection of the EGFR mutation state are beneficial for selecting appropriate treatments.

View Figures

View References

1	Langevin SM, Kratzke RA and Kelsey KT: Epigenetics of lung cancer. Transl Res. March 12–2014.(Epub ahead of print).
2	Shigematsu H and Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 118:257–262. 2006.
3	Xu L, Kikuchi E, Xu C, et al: Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res. 72:3302–3311. 2012.
4	Witta SE, Jotte RM, Konduri K, et al: Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 30:2248–2255. 2012.
5	D’Incecco A and Cappuzzo F: Gefitinib for non-small-cell lung cancer treatment. Expert Opin Drug Saf. 10:987–996. 2011.
6	Costanzo R, Piccirillo MC, Sandomenico C, et al: Gefitinib in non small cell lung cancer. J Biomed Biotechnol. 2011:8152692011.
7	Kobayashi T, Takeda M, Marumo S, Koshimo Y, Teranishi T, Higami Y and Kato M: Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases. Lung Cancer. 80:109–111. 2013.
8	Pao W and Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 10:760–774. 2010.
9	Tokumo M, Toyooka S, Ichihara S, et al: Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer. 53:117–121. 2006.
10	Wrona A and Jassem J: The new TNM classification in lung cancer. Pneumonol Alergol Pol. 78:407–417. 2010.(In Polish).
11	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004.
12	Sequist LV, Martins RG, Spigel D, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 26:2442–2449. 2008.
13	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004.
14	Cortes-Funes H, Gomez C, Rosell R, et al: Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol. 16:1081–1086. 2005.
15	Weiss GJ, Liman AK, Allen J, et al: Squamous cell carcinoma of the lung with metastasis to the GI tract associated with EGFR exon 19 deletion. Case Rep Med. 2013:8748362013.
16	Fang W, Zhang J, Liang W, et al: Efficacy of epidermal growth facor receptor-tyrosine kinase inhibitors for Chinese patients with squamous carcinoma of lung harboring EGFR mutation. J Thorac Dis. 5:585–592. 2013.
17	Khozin S, Blumenthal GM, Jiang X, et al: U.S. Food and Drug Administration Approval Summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist. May 27–2014.(Epub ahead of print).
18	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009.
19	Rosell R, Moran T, Queralt C, et al: Spanish Lung Cancer Group: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 361:958–967. 2009.
20	Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 28(Suppl 1): S24–S31. 2009.
21	Shigematsu H and Gazdar AF: Mutations of EGFR in lung cancers and their implications for targeted therapy. Discov Med. 4:444–447. 2004.
22	Shigematsu H and Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 118:257–262. 2006.
23	Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA and Pao W: Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res. 14:7519–7525. 2008.